The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2016 | What has changed in AML treatment in the last 30 years?
Antonio Pagliuca
• 4 Apr 2016
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses improvements in supportive care and diagnostics for acute myeloid leukemia (AML). Further work is required to improve outcomes of high-risk patients.
